Stocks
Intelligent OutlookABBV-
Intelligent Outlook
ABBV-
Prev Close-
50D MA-
200D MA-
52W High-
Live Price
ABBV 24H Rolling
0.000.00%0.00
Rolling: Last 24h | 5m
ABBV
Asset Information
Company Profile
Company:ABBV
Sector:Biotechnology
Industry:Biotechnology
Country:US
Employees:55,000
IPO Date:2012-12-10
Website:www.abbvie.com/
Technicals & Growth
Market Cap:$381.38B
Shares O/S:1,766,558,253
52W High:$244.81
52W Low:$163.81
50D MA:$222.40
200D MA:$199.74
Financial Ratios
P/E Ratio:164.80
EPS:$1.31
Profit Margin:6.84%
ROE (TTM):-131.13%
ROA (TTM):3.16%
Div. Per Share:$6.92
ABBV
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Loading chart library...
Financial Data (Macrotrends)
Historical Data
Loading...